Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish

Shares of biotechnology company Prime Medicine, Inc. (PRME) fell 18% on Monday afternoon after the company announced a strategic restructuring, including layoffs and the resignation of its CEO in a bid to reduce cash burn.

Prime Medicine announced that Keith Gottesdiener will step down as CEO and a member of the company’s board of directors, effective immediately.

Allan Reine, Prime Medicine’s Chief Financial Officer (CFO), will now succeed Gottesdiener.

The company also announced the deprioritization of its programs aimed at the genetic disorder Chronic Granulomatous Disease (CGD), instead focusing its efforts on the development of programs for genetic liver diseases, Wilson’s Disease, and Alpha-1 Antitrypsin Deficiency (AATD).

The company expects to file an investigational new drug (IND) and/or clinical trial application (CTA) for its Wilson’s Disease program in the first half of 2026 and its AATD program in mid-2026. Initial clinical data from both programs is expected the following year.

For its CGD program, PM359, the company said it is exploring options for continued clinical development outside the firm.

However, the company expressed confidence in the program and believes it has the potential to transform the treatment of the disorder.

Prime Medicine also said it is reducing its organizational headcount by approximately 25%.

The company believes the multiple initiatives will reduce anticipated cash needs by almost half through 2027.

Prime Medicine expects that its cash, cash equivalents, and investments as of March 31, 2025, will be sufficient to fund its operations and capital expenditure requirements into the first half of 2026.

On Stocktwits, retail sentiment around PRME rose within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.

PRME stock is down by about 57% this year and 83% over the past 12 months.

Also See: Protagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely Bullish

For updates and corrections, email newsroom[at]stocktwits[dot]com.